Everlight Chemical Industrial Corporation Overview
Everlight Chemical is a 54-year-old Taiwanese fine- and specialty-chemicals group that is partway through a transition from a dye maker into a supplier of electronic and semiconductor materials. It runs five business units: Color Chemicals (textile reactive and disperse dyes, digital-textile inks), Specialty Chemicals (Eversorb® UV absorbers and hindered-amine light stabilisers), Electronic Chemicals (photoresists, developers, CMP slurries, wet-process chemicals, PSPI), Toner (through subsidiary 全通科技), and Pharmaceutical Chemicals (prostaglandin and other APIs). Consolidated revenue fell from NT$9.20 billion in FY2021 to NT$7.57 billion in FY2025, and FY2025 was a loss year. In 2026, however, Electronic Chemicals has become the second-largest unit, driven by photoresist contract manufacturing for international (mainly Japanese) chemical majors and by localisation of advanced-packaging supply chains. The equity now trades as a semiconductor-materials story, at roughly 3x book value. The company is raising new equity to fund electronic-chemical capacity.
Company's own description
The company's corporate website and annual-report summary describe Everlight as a company founded in 1972 under the philosophy of "pursuing progress and innovation, promoting humanity, and enhancing human welfare," with the cultural core of "honest operation and caring management." It describes its own trajectory as moving step by step from a traditional dye company into a "high-tech chemical enterprise group" with five businesses: color chemicals, specialty chemicals, toner, electronic chemicals and pharmaceutical chemicals. The company states that it has more than 1,800 employees worldwide, about 20 operating sites and 6 production bases (5 in Taiwan, 1 in Suzhou, China), and a sales network covering more than 100 countries on five continents. It also states that it spends more than 4% of revenue on R&D each year, employs about 200 R&D staff, and holds more than 200 patents.
S&P Global's business description, as reproduced by StockAnalysis, says the company sells chemical products and related raw materials in China, Taiwan, Europe, Asia, the Americas and elsewhere, and reports Pigment Chemistry, Specialty Chemicals, Pharmaceuticals Chemistry, Electronic Chemicals and Toner segments. Its product scope includes dyes for textiles, leather, inkjet, metal and paper; textile functional chemicals; digital textile inkjet inks; solar-sensitised dyes; and light stabilisers for coatings, plastics and PU/TPU.
Independent characterisation
| Business unit | Customer type | End markets |
|---|---|---|
| Color Chemicals | Textile dyeing and printing mills, digital-print houses, brand-mandated supply chains | Apparel, home textiles, sportswear (management noted demand from sporting events), leather, paper |
| Specialty Chemicals | Plastics compounders, coatings formulators, agricultural film makers, cosmetics, contact-lens makers | Automotive coatings, construction plastics, agri-film, solar encapsulants, personal care, ophthalmic |
| Electronic Chemicals | Display panel makers, LED/Mini/Micro-LED makers, semiconductor fabs and OSATs, chemical majors (contract manufacturing) | Displays, power semiconductors, advanced packaging, SiC substrates |
| Toner | Compatible-cartridge makers and OEMs | Office printing |
| Pharmaceutical Chemicals | Generic and branded drug makers in 40+ countries | Ophthalmology (prostaglandins such as latanoprost), cardiovascular (e.g., felodipine), oncology, veterinary |
Everlight is a mid-cap, family-controlled, multi-niche specialty chemicals company with a manufacturing-led business model. Its core competency is organic synthesis and purification know-how built in azo and reactive dye chemistry. Over three decades the company has applied that know-how to:
-
UV-absorber and light-stabiliser molecules (Eversorb®), where it competes with BASF's Tinuvin range. It began development in 1989 and started production in 1996.
-
Photoactive and electronic materials, built on technology transferred from ITRI beginning in 1995. The company built a dedicated electronic chemicals plant in 1997.
-
Prostaglandin and other high-potency APIs, with development from 1992 and a GMP plant completed in 1998.
-
Chemically prepared toner, entered through the 1997 acquisition of 全通科技.
Revenue model. The business is almost entirely product revenue: chemicals sold by the kilogram or tonne. There is a growing contract-manufacturing (toll/OEM) component, mainly photoresist and other electronic chemicals made for international chemical majors that management describes as mostly Japanese. Management also mentioned a US company seeking non-China capacity. The contract-manufacturing share of revenue is not disclosed separately. There is no meaningful subscription or licensing revenue, although the company has received ITRI technology licences (as licensee) for photoresist and PSPI.
Value-chain position. Everlight sits in the middle of the chemical value chain. It buys petrochemical intermediates (naphthalene, phenols and other aromatics), acids, alkalis, salts and solvents, and for toner it buys acrylic/polyester resins, magnetic iron oxide and carbon black. It sells formulated or high-purity molecules to industrial converters: textile dyehouses, plastics and coatings compounders, display and semiconductor fabs and packaging houses, printer-cartridge makers and generic drug makers.
Customer types and end markets.
FX exposure. At the August 2025 investor conference, management said about 80% of transactions are priced in US dollars. On their estimate, a 10% appreciation of the TWD reduces revenue by about 8%, and each 1% TWD appreciation lowers gross profit by about 0.3–0.4%.
Strategy
Stated strategy (themes from 2025–2026 investor conferences and annual reporting)
Management's stated strategy has five themes:
-
Portfolio migration to Electronic Chemicals. Redeploy resources and capacity from Color Chemicals to Electronic Chemicals and niche high-value products. Lift Electronic Chemicals to 25–30% of revenue (target stated in August 2025); it reached "nearly one quarter" in 2026.
-
Semiconductor localisation and contract manufacturing. Take on contract manufacturing from international chemical majors, mainly Japanese, especially back-end advanced-packaging photoresists. Customers have asked Everlight to invest in capacity for them. Engage with US majors that want non-China capacity to serve China.
-
Own-brand advanced materials. Expand sales of own-brand photoresists (PSPI, low-temperature OC and BM) and target front-end semiconductor process chemicals, back-end packaging PSPI, and low-temperature display materials for flexible displays and FOPLP.
-
Defend legacy businesses through mix and pricing.
-
Color: pass costs through precisely in what management now describes as a seller's market, control inventory, push environmentally advantaged products, grow high-margin products, and adjust pricing models to be more resilient to FX and raw materials. Grow own-brand products.
-
Specialty: differentiated competition and flexible pricing to protect margins; faster new-product development.
-
Toner: substitute lower-cost raw materials, expand regional markets, and complete "the last mile" of restructuring.
-
-
Green chemistry, circular economy and ZDHC leadership as commercial differentiators in textile supply chains.
Initiatives in the last 24 months
| Initiative | Timing | Detail | Status |
|---|---|---|---|
| Advanced-packaging photoresist contract-manufacturing line | 2025–2026 | New line built at customers' request; nearly complete April 2026 | Ramping; contributing quarterly |
| PSPI (EverPI P07) qualification | Sampling since 2025, accelerated after the 2026 Japanese supply shortage | Supplying power-semiconductor customers; advanced-packaging qualification ongoing as second or third source | Not yet adopted in volume for advanced packaging (as of Apr and Oct 2026) |
| Electronic-chemical capacity expansion | Announced 2026 | New production lines plus a hazardous-goods cold-storage warehouse at Taoyuan | Funded by the cash capital increase |
| 50 million-share cash capital increase | Approved 13 Aug 2026; effective 1 Oct 2026 | 40 million to existing holders, 5 million to employees, 5 million public offering | Pricing pending; payment period Nov 2026 |
| Contact-lens anti-blue-light UVA | 2025–2026 | Patented reactive UVA; orders from a "world-class" contract manufacturer | Early commercial |
| Perovskite PV encapsulant | 2025–2026 | Working with Taiwanese partners; management cites recognition in Nature | Early stage; small volumes |
| Eversorb 990 for PE agri-films | c.2024 | Weatherability upgrade | Commercial |
| Smart manufacturing (Plant 2) | 2023 onward | Yokogawa S.I.R.I. roadmap | Implementation not quantified |
| GHG reduction | Target set 2023 report | −25% by 2030, aligned with Taiwan's 2050 net-zero path | In progress |
Medium-term targets and guidance
Everlight does not publish numerical revenue or earnings guidance. Management's qualitative stance at the April 2026 conference was cautious on global end-demand for Q2 and H2 2026, apart from textile demand tied to sporting events. Management said part of the March–April 2026 rebound reflected precautionary pull-forward buying driven by fears of supply-chain disruption. It was positive on electronic chemicals and contract manufacturing. Sell-side expectations reported in Taiwanese press (mid-2026) were for "high double-digit" profit growth in 2026. That expectation is not attributable to a named broker. The historical "NT$10 billion revenue" aspiration from the 2022 anniversary has not been reiterated as a dated target.
Products & Services
The company does not publish price lists. Pricing is negotiated (spot or contract for dyes and UVA; pre-agreed contract pricing for contract manufacturing). Management said in April 2026 that it is renegotiating contract-manufacturing price mechanisms to better absorb FX and raw-material swings.
Color Chemicals
| Product line | Description and capabilities | Target customer | Latest notable version / year | Notes |
|---|---|---|---|---|
| Everzol® reactive dyes | Reactive dyes for cellulosic (cotton) fibres; high-exhaustion, energy-saving grades | Cotton dyehouses | Everzol® CS series (earth tones for cotton) won an MOEA Taiwan Excellence Gold Award in the 2020s | Plant 1 verified Everzol Black-B 133% under ISO 14051 MFCA |
| Disperse dyes | Dyes for polyester and blends | Synthetic-fibre dyehouses, sportswear chains | — | Demand linked to sports events (Apr 2026 call) |
| Digital textile inks | Reactive, acid and disperse inkjet inks for digital textile printing, incl. cotton and silk | Digital print houses | Ongoing | Positioned as the low-energy, low-water route |
| Leather, paper and metal dyes | Specialty colourants | Tanneries, paper mills, anodisers | — | Smaller lines |
| Textile functional chemicals / auxiliaries | Process auxiliaries | Dyehouses | — | ZDHC MRSL-conformant |
| Solar-sensitised dyes | Dyes for dye-sensitised solar cells | PV developers | — | Produced at Plant 4 |
Specialty Chemicals
| Product line | Description | Target customer | Year / version | Notes |
|---|---|---|---|---|
| Eversorb® UV absorbers (benzotriazole, triazine, benzophenone classes) | UV protection for plastics, coatings, adhesives, PU/TPU | Compounders, coatings formulators | Production since 1996 | Company says the range complies with international regulations |
| Eversorb® HALS | Radical-scavenging light stabilisers | Same | Ongoing | — |
| Eversorb 990 | Stabiliser for polyethylene agricultural films | Agri-film makers | Launched c.2024 (per 2024 annual-report summary on ROIC.ai) | Weatherability |
| Reactive anti-blue-light UVA | Patented reactive UV absorber blocking 400–460 nm | Contact-lens makers (a "world-class contract manufacturer" order disclosed) | Commercial 2025–26 | >1,000x conventional UVA unit price |
| Perovskite solar encapsulant | Encapsulation adhesive for perovskite PV | PV developers, Taiwanese partners | Early commercial stage | Management cites recognition in a Nature report |
| Anti-yellowing agents | For PU and textiles | PU/textile processors | — | — |
Electronic Chemicals
| Product line | Description | Target customer | Status | Notes |
|---|---|---|---|---|
| Photoresists (display) | Resists for TFT-LCD, touch panels, AMOLED | Panel makers | Mature; mix shifted to small-size and AMOLED | — |
| Low-temperature OC and BM photoresists | Overcoat and black-matrix resists for low-temperature, flexible displays and FOPLP | Display and panel-level packaging makers | Commercial, own brand | — |
| Mini/Micro-LED photoresists | Resists for LED patterning | LED makers | Growth driver 2024–25 | Company says it is displacing foreign suppliers |
| Advanced-packaging photoresists (contract) | Back-end thick-film or chemically amplified resists made under contract for international chemical majors | Japanese chemical majors; US major in discussion | New line nearly complete (Apr 2026), ramping quarterly | Key 2026 growth driver |
| EverPI® P07 (positive PSPI) | Photosensitive polyimide for redistribution and passivation layers | Power-semiconductor customers (in production); advanced-packaging/foundry (sampling) | Supplying power semis; advanced-packaging sampling, positioned as second or third source | Technology from an ITRI transfer about five years ago; early use in automotive |
| Negative PSPI | Under development | Packaging houses | Development | — |
| CMP / polishing slurries | Incl. SiC substrate polishing slurry | SiC wafer makers | Adopted by customers, notably in China | — |
| Wet-process chemicals | Semiconductor front-end wet chemicals | Fabs | Drove H1 2024 growth per the President | — |
| Developers, thermal/UV-curable functional inks | Process chemicals | Display and PCB makers | Ongoing | — |
Toner (全通科技)
| Product line | Description | Target customer | Notes |
|---|---|---|---|
| Mono and colour toner | Positive- and negative-charge toners for laser printers and copiers | Compatible-cartridge makers, OEMs | Capacity about 4,000 t/yr in 2010 with a 2,000 t line added (Commercial Times, 2010); current capacity not disclosed |
| Toner cartridges, carriers, developers | Finished consumables | Same | US customers looking for non-China sources (2026 commentary) |
Pharmaceutical Chemicals
| Product line | Description | Target customer | Notes |
|---|---|---|---|
| Prostaglandin APIs (e.g., latanoprost) | Ophthalmic glaucoma APIs | Generic drug makers | Developed since 1992; registered in US, Canada, EU, UK, Japan, China |
| Cardiovascular APIs (e.g., felodipine) | — | Generic drug makers | DMF-type registrations at the Kuanyin II plant |
| Oncology APIs | — | Same | — |
| Veterinary APIs | — | Animal-health makers | — |
| CDMO services | Custom synthesis | Pharma clients | 2024 growth attributed to CDMO and launches into EU, US, Japan and LatAm |
Regulatory status: the Plant 2 API facility is on the Taiwan FDA PIC/S GMP list. The company reports certification or inspection by Taiwan FDA, US FDA, EU authorities and Japan's PMDA. The latest US FDA inspection identified in sources was October 2019, classified VAI and closed via EIR.
Financial Narrative
Source: consolidated IFRS financial statements as compiled by S&P Global Market Intelligence (via StockAnalysis.com), cross-checked against company investor-conference disclosures. TWD millions unless stated.
Margins
Revenue CAGR: FY2021–FY2025 (4 years) ≈ −4.8% p.a. (derived). FY2020–FY2025 (5 years, FY2020 revenue NT$7,769 million per ROIC.ai) ≈ −0.5% p.a. (derived).
Quarterly trajectory (FY2025–H1 2026)
Q4 2025 EPS is −0.03 per CMoney and −0.04 per Yahoo (rounding). Q2 2026 margins were not available in sources accessed. The table uses "—" because they are not disclosed here. H1 2026 consolidated net profit was NT$155 million with EPS NT$0.28 (Yahoo/MOPS headline).
Balance sheet
Goodwill: none separately reported. Intangibles are immaterial at under 1% of assets.
Latest balance sheet (30 June 2026): total assets NT$14,026 million; cash and short-term investments NT$1,421 million; total debt NT$3,184 million (short-term debt NT$2,257 million, long-term NT$700 million); net debt NT$1,763 million; total equity NT$9,171 million; book value per share NT$16.29. The NT$669 million rise in "comprehensive income and other" in H1 2026 is consistent with mark-to-market gains on long-term equity investments; long-term investments rose from NT$897 million to NT$1,449 million.
Cash flow
Dividends paid in a calendar year relate to the prior year's earnings: NT$0.30/share paid in 2021 (FY2020), 0.50 in 2022, 0.35 in 2023, 0.15 in 2024, 0.30 in 2025, and none in 2026. No buyback programme was identified; S&P records a small "buyback yield" of 0.14–0.19% in some years, which is immaterial.
Commentary on trends, inflections and drivers
Revenue. FY2021 was a post-COVID restocking peak, with revenue up 18.4% on textile and toner demand. The following three years show a structural de-rating of the legacy businesses. Color Chemicals lost about NT$1.44 billion of revenue between FY2021 and FY2025 (−34%), as Chinese dye producers expanded capacity and global apparel destocked in 2022–23. Electronic Chemicals is the only unit with a sustained positive trend, growing from NT$1.23 billion to NT$1.82 billion (+48%) over the same period. FY2025's 7.3% decline came from two external shocks that management named explicitly: US tariff policy, which froze textile and consumer-goods supply chains from Q2 2025, and the strong appreciation of the TWD, which hit a revenue base that is about 80% USD-priced. Monthly revenue fell 15–17% YoY in May and June 2025.
Margins. Gross margin has fallen by about 500 bp in four years, from 24.1% to 19.0%. The trough was Q3 2025 at 15.95%, when FX, under-absorption and price competition in dyes and UVA all hit together. Operating leverage is high. SG&A plus R&D runs at about NT$1.6 billion a year (G&A NT$1.26 billion and R&D NT$0.38 billion in FY2025, per Simply Wall St), so a 1-point change in gross margin moves operating income by about NT$75–80 million. That explains why operating income swung from +NT$175 million to −NT$196 million on a 7% revenue decline. Q1 2026 gross margin recovered to 21.5%, the best in four quarters, and Q2 2026 EPS of NT$0.19 was the best single quarter since at least 2022.
Earnings quality. Non-operating items matter. H1 2025 had an FX loss of NT$62 million against a NT$65 million gain a year earlier, a NT$127 million swing. In November 2025, non-operating income turned an operating loss into a pre-tax profit. In Q1 2026, pre-tax profit (NT$66 million) was more than double operating profit (NT$30 million).
Balance sheet. Leverage is moderate. Net debt has been stable at NT$1.5–1.8 billion, and debt/equity has stayed around 0.35x through the cycle. The structure is weighted to short-term bank borrowing, with about NT$1.85–2.26 billion of short-term loans rolled continuously; this is typical for Taiwanese mid-caps. Liquidity is adequate but the quick ratio is below 1.0x because the business is inventory-heavy: DIO of 185–210 days reflects the wide range of dye SKUs.
Cash flow. Cash generation has weakened sharply. Free cash flow fell from NT$700 million in FY2023 to NT$62 million in FY2025 as capex more than tripled from NT$233 million in FY2021 to NT$776 million in FY2025, while operating cash flow fell. Construction in progress rose to NT$1.02 billion at FY2025, the electronic-chemical expansion and photoresist line, from NT$0.13–0.14 billion in FY2021–22. This capex step-up, combined with the April 2026 statement that expansion would be funded from internal cash and bank loans with "no current plan" for a cash capital increase or CB, sets the context for the August 2026 reversal to a 50 million-share equity raise.
Returns. ROE has never exceeded 5.5% in the five-year window and has been below the cost of equity throughout. The 2026 equity re-rating to about 3x book value therefore depends on a step change in returns from the electronic-chemicals mix, not on the historical return profile.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Business Units
| Unit | Contents | Representative products |
|---|---|---|
Color Chemicals (色料化學品) | Textile dyes, digital textile inks, leather, paper and metal dyes, textile auxiliaries | Everzol® reactive dyes (incl. CS series earth tones for cotton), Everlight disperse dyes, digital textile inks for cotton and silk |
Specialty Chemicals (特用化學品) | UV absorbers, hindered-amine light stabilisers, anti-yellowing agents, specialty UVA for optics | Eversorb® UVA/HALS range, incl. Eversorb 990 for PE agricultural films; reactive anti-blue-light UVA for contact lenses |
Electronic Chemicals (電子化學品, incl. nano-materials) | Photoresists, developers, CMP/polishing slurries, wet-process chemicals, functional inks, PSPI, contract manufacturing | EverPI® P07 (positive PSPI), low-temperature OC (overcoat) and BM (black matrix) resists, SiC substrate slurry, Mini/Micro-LED resists |
Toner (碳粉) | Mono and colour toner, cartridges, carriers, developers | Made by subsidiary 全通科技 (Hsinchu) |
Pharmaceutical Chemicals (醫藥化學品) | APIs and CDMO | Prostaglandin APIs (e.g., latanoprost), cardiovascular (felodipine), oncology, veterinary APIs |
Revenue by Segment
| Segment (Revenue, TWD Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Color Chemicals Revenue (TWD Mn) | 4,196 | 3,514 | 3,143 | 3,012 | 2,756 |
Specialty Chemicals Revenue (TWD Mn) | 2,365 | 2,427 | 2,012 | 2,101 | 1,814 |
Electronic Chemicals Revenue (TWD Mn) | 1,229 | 1,314 | 1,323 | 1,696 | 1,821 |
Toner Revenue (TWD Mn) | 1,170 | 1,404 | 1,162 | 1,134 | 974 |
Pharmaceutical Chemicals Revenue (TWD Mn) | 241 | 233 | 220 | 226 | 204 |
Total Segment Revenue (TWD Mn) | 9,201 | 8,897 | 7,875 | 8,168 | 7,569 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment Margins & Growth (%)
| Segment (YoY growth %) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Color Chemicals YoY (%) | -16.3 | -10.6 | -4.2 | -8.5 |
Specialty Chemicals YoY (%) | 2.6 | -17.1 | 4.4 | -13.7 |
Electronic Chemicals YoY (%) | 6.9 | 0.7 | 28.2 | 7.4 |
Toner YoY (%) | 20.0 | -17.2 | -2.4 | -14.1 |
Pharmaceutical Chemicals YoY (%) | -3.4 | -5.6 | 2.7 | -9.7 |
Revenue by Segment (%)
| Segment (% of total) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Color Chemicals (%) | 45.6 | 39.5 | 39.9 | 36.9 | 36.4 |
Specialty Chemicals (%) | 25.7 | 27.3 | 25.5 | 25.7 | 24.0 |
Electronic Chemicals (%) | 13.4 | 14.8 | 16.8 | 20.8 | 24.1 |
Toner (%) | 12.7 | 15.8 | 14.8 | 13.9 | 12.9 |
Pharmaceutical Chemicals (%) | 2.6 | 2.6 | 2.8 | 2.8 | 2.7 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment (H1 2025) Overview
| Segment (H1 2025) | Revenue (TWD Mn) | YoY | Share of revenue | Segment profit (TWD Mn) | Profit change YoY |
|---|---|---|---|---|---|
Color Chemicals | 1,539 | +3% | 39% | 78 | −103 |
Specialty Chemicals | 975 | −13% | 25% | 44 | −101 |
Electronic Chemicals | 874 | +13% | 22% | 49 | Flat |
Toner | — | — | — | Loss widening (Apr 2026 call) | — |
“—” = not publicly disclosed.
Segment Revenue
| Segment | Jan–Aug 2026 revenue (TWD Mn) | YoY | Aug 2026 revenue (TWD Mn) | Aug YoY |
|---|---|---|---|---|
Color Chemicals | 1,961 | +2% | 251 | +22% |
Specialty Chemicals | 1,407 | +11% | 168 | +13% |
Electronic Chemicals | 1,591 | +36% | 271 | +86% |
Toner | ≈632 (derived residual; press figure of 74.34 appears to repeat the monthly number) | ≈+1% (reported) | 74.34 | +31% |
Pharmaceutical | 114 | −10% | 5.98 | −63% |
Total | 5,705 | +11.64% | 747 | +33.16% |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (TWD Mn) | 9,201 | 8,892 | 7,861 | 8,168 | 7,569 |
Revenue growth (%) | 18.43 | -3.36 | -11.59 | 3.90 | -7.34 |
Gross profit (TWD Mn) | 2,213 | 1,995 | 1,600 | 1,787 | 1,436 |
Operating income (TWD Mn) | 553 | 381 | 83 | 175 | -196 |
Depreciation & amortisation (TWD Mn) | 701 | 673 | 652 | 666 | 659 |
EBITDA, derived = EBIT + D&A (TWD Mn) | 1,254 | 1,054 | 735 | 841 | 463 |
Pre-tax income (TWD Mn) | 597 | 484 | 109 | 286 | -173 |
Net income (TWD Mn, S&P) | 473 | 374 | 86 | 244 | -117 |
EPS basic (TWD) | 0.86 | 0.68 | 0.16 | 0.44 | -0.21 |
EPS diluted (TWD) | 0.86 | 0.68 | 0.16 | 0.44 | -0.21 |
Cash dividend per share declared from FY earnings (TWD) | 0.50 | 0.35 | 0.15 | 0.30 | 0.00 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin (%) | 24.06 | 22.44 | 20.35 | 21.88 | 18.97 |
Operating margin (%) | 6.01 | 4.28 | 1.06 | 2.15 | -2.59 |
EBITDA margin, derived (%) | 13.6 | 11.9 | 9.4 | 10.3 | 6.1 |
Pre-tax margin (%) | 6.49 | 5.44 | 1.39 | 3.50 | -2.29 |
Net margin (%) | 5.14 | 4.21 | 1.09 | 2.98 | -1.55 |
Income Statement and Margin Analysis (%) (Quarterly)
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|
Revenue (TWD Mn) | 1,941 | 1,987 | 1,806 | 1,835 | 2,045 | 2,132 |
Gross margin (%) | 22.32 | 19.68 | 15.95 | 17.63 | 21.52 | — |
Operating margin (%) | 1.02 | -0.98 | -5.61 | -5.18 | 1.83 | — |
EPS (TWD) | 0.07 | -0.13 | -0.11 | -0.04 | 0.09 | 0.19 |
Balance Sheet and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (TWD Mn) | 14,136 | 13,133 | 12,901 | 13,243 | 12,794 |
Cash & short-term investments (TWD Mn) | 1,540 | 1,219 | 1,507 | 1,366 | 1,217 |
Short-term debt incl. current LTD (TWD Mn) | 2,056 | 1,678 | 1,741 | 1,779 | 1,892 |
Long-term debt (TWD Mn) | 1,000 | 1,088 | 1,006 | 864 | 821 |
Total debt incl. leases (TWD Mn) | 3,328 | 3,035 | 3,005 | 2,885 | 2,949 |
Net debt (TWD Mn) | 1,788 | 1,815 | 1,498 | 1,519 | 1,732 |
Total equity incl. minorities (TWD Mn) | 9,106 | 8,807 | 8,656 | 8,809 | 8,436 |
Equity attributable to parent (TWD Mn) | 8,806 | 8,455 | 8,344 | 8,536 | 8,177 |
Intangible assets (TWD Mn) | 5 | 62 | 53 | 98 | 74 |
Inventory (TWD Mn) | 3,530 | 3,971 | 3,390 | 3,423 | 3,125 |
Receivables (TWD Mn) | 1,889 | 1,558 | 1,663 | 1,816 | 1,664 |
Working capital (TWD Mn) | 3,619 | 4,135 | 3,828 | 3,689 | 3,080 |
Construction in progress (TWD Mn) | 143 | 126 | 296 | 491 | 1,023 |
Book value per share (TWD) | 16.08 | 15.44 | 15.23 | 15.58 | 14.93 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (TWD Mn) | 757 | 853 | 1,336 | 980 | 838 |
Capital expenditure (TWD Mn) | 233 | 363 | 636 | 678 | 776 |
Free cash flow (TWD Mn) | 524 | 490 | 700 | 302 | 62 |
Common dividends paid (TWD Mn) | 164 | 274 | 192 | 82 | 164 |
Share buybacks (TWD Mn) | 0 | 0 | 0 | 0 | 0 |
Cash interest paid (TWD Mn) | 51 | 71 | 102 | 107 | 99 |
Change in working capital (TWD Mn) | -520 | -279 | 520 | -27 | 314 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE (%) | 5.51 | 4.38 | 1.09 | 2.90 | -1.58 |
ROA (%) | 2.53 | 1.75 | 0.40 | 0.84 | -0.94 |
ROIC (%) | 4.18 | 2.87 | 0.70 | 1.52 | -1.91 |
Current ratio (x) | 2.06 | 2.49 | 2.34 | 2.20 | 1.99 |
Quick ratio (x) | 1.00 | 1.00 | 1.11 | 1.03 | 0.93 |
Debt / equity (x) | 0.37 | 0.35 | 0.35 | 0.33 | 0.35 |
Net debt / EBITDA (x, S&P) | 1.47 | 1.79 | 2.15 | 1.89 | 4.06 |
Interest coverage, EBIT / cash interest (x, derived) | 10.9 | 5.3 | 0.8 | 1.6 | -2.0 |
Asset turnover (x) | 0.67 | 0.65 | 0.60 | 0.63 | 0.58 |
Inventory turnover (x) | 2.08 | 1.84 | 1.70 | 1.87 | 1.87 |
DSO, year-end (days, derived) | 73 | 63 | 75 | 78 | 78 |
DIO, year-end (days, derived) | 184 | 210 | 198 | 196 | 186 |
DPO, year-end (days, derived) | 30 | 23 | 34 | 41 | 36 |
Cash conversion cycle (days, derived) | 227 | 250 | 239 | 233 | 228 |
Data Point Details
| Data point | Value | Source |
|---|---|---|
Regions of sale | China, Taiwan, rest of Asia, Europe, Americas, other | S&P / Yahoo company description |
Currency of transactions | About 80% USD-denominated | 26 Aug 2025 investor conference |
Suzhou plant share of production value | About 20–25% (serving China domestic color and specialty demand) | Third-party analysis (uc913.com, Oct 2026); not company-verified |
Overseas subsidiaries | USA (1991), Hong Kong (1992), Singapore (1997), Turkey/Mersin (1989), Suzhou (2006) | Company history page |
China-specific trend | Electronic Chemicals: SiC slurry and photoresist growth "notably in mainland China" (H1 2025). Group revenue hit by "decline in the Chinese market" in 2025 (财讯快报, mid-2026). | Press summaries of company conferences |
Japan | Main source of contract-manufacturing partners (Japanese chemical majors) | Apr 2026 conference |
United States | Tariff-driven demand freeze in 2025. US toner and chemical customers seeking non-China sources in 2026. | Apr 2026 conference |
Share Price and Market Valuation
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Year-end close price (TWD) | 25.52 | 17.72 | 19.10 | 20.62 | 19.15 |
Year-end market cap (TWD Mn) | 14,926 | 10,133 | 10,736 | 11,503 | 10,489 |
P/E at year-end (x) | 31.56 | 27.06 | 125.03 | 47.22 | 0 |
P/B at year-end (x) | 1.64 | 1.15 | 1.24 | 1.31 | 1.24 |
EV/EBITDA at year-end (x) | 14.09 | 12.28 | 18.42 | 16.33 | 29.58 |
EV/Sales at year-end (x) | 1.86 | 1.40 | 1.64 | 1.61 | 1.67 |
Performance Details
| Performance (to close of 6 Oct 2026, NT$48.60) | Return (price only, derived) | Basis |
|---|---|---|
Year-to-date 2026 | +154% | vs. 31 Dec 2025 close NT$19.15 |
≈3-year | +154% | vs. 31 Dec 2023 close NT$19.10 (proxy) |
≈5-year | +90% | vs. 31 Dec 2021 close NT$25.52 (proxy) |
1-year | Not precisely verified. The 52-week low of about NT$17.05 (cnyes) implies a roughly 185% gain from the low; StockAnalysis showed market cap +181% YoY in mid-2026. | Proxy |
52-week range | About NT$17.05 – NT$64.30 | cnyes |
Valuation Multiples
| Multiple | Everlight | Basis |
|---|---|---|
Market cap | ≈NT$26.6 bn | 547.16 m shares × NT$48.60 |
Enterprise value | ≈NT$28.6 bn |
|
P/E (TTM) | ≈374x | TTM EPS NT$0.13 (Q3'25 −0.11, Q4'25 −0.04, Q1'26 0.09, Q2'26 0.19) |
P/B | ≈2.98x | BVPS NT$16.29 (Jun 2026) |
EV/Sales (TTM) | ≈3.7x | TTM revenue ≈NT$7.82 bn (FY2025 − H1'25 + H1'26) |
EV/EBITDA (TTM) | ≈60x | TTM-Mar-2026 EBITDA ≈NT$478 m implied by S&P (EV NT$21.43 bn / 44.86x) |
Per-Share Data and Returns & Leverage Ratios (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Cash dividend per share declared from FY earnings (TWD) | 0.50 | 0.35 | 0.15 | 0.30 | 0.00 |
Payout ratio (%) | 58 | 51 | 94 | 68 | 0 |
Analyst Conclusions
Management guidance
There is no quantitative guidance. The qualitative message (28 April 2026) is cautious on global end-demand for Q2 and H2 2026, apart from textile demand tied to sporting events. Management noted that part of the March–April rebound was pre-buying. It was constructive on contract-manufacturing volumes rising "quarter by quarter," on Electronic Chemicals reaching about a quarter of revenue, and on new high-value products (contact-lens UVA, perovskite encapsulant). Funding for the expansion has changed: from "internal funds and bank loans, no current SPO plan" in April 2026 to a 50 million-share SPO in August 2026.
Consensus growth expectations
No formal consensus exists. Reported institutional expectations point to high double-digit profit growth in 2026 from the loss base of FY2025. Year-to-date data are consistent with this: Jan–Aug 2026 revenue was +11.6% and H1 EPS NT$0.28 against −NT$0.06 in H1 2025.
Bull case
-
Mix-driven margin expansion. Electronic Chemicals grew 36% YTD to August 2026 while legacy units are flat to up mid-single digits. Each additional NT$1 billion of electronic revenue, at margins above the group's 19–22% gross margin, flows through a largely fixed SG&A base of about NT$1.6 billion. That could lift operating margin back above the FY2021 level of 6%.
-
Capacity-backed contract manufacturing. The dedicated advanced-packaging photoresist line was built at customer request, and SPO proceeds add further electronic lines. This makes revenue more visible than a speculative own-brand ramp.
-
PSPI optionality. Qualifying as a second or third source for advanced-packaging PSPI would add a high-margin, sticky permanent material. The company states PSPI margins are above the segment average, and switching costs protect incumbents once qualified.
Bear case
-
Valuation already discounts success. About 374x trailing P/E, about 3.0x P/B and about 60x EV/EBITDA, for a company whose five-year peak ROE was 5.5%.
-
Qualification uncertainty and narrative risk. Management has repeatedly said PSPI for advanced packaging is still sampling. April 2026 press claims of adoption were not borne out, and the stock moved through limit-up and limit-down sessions on those headlines.
-
The legacy base still dominates. Color, Specialty and Toner made up about 73% of FY2025 revenue and declined 8–14% that year. They are exposed to FX (about 80% USD), tariffs and Chinese competition. Free cash flow fell to NT$62 million and is now being supplemented by dilutive equity.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Timing | What to watch |
|---|---|---|
| SPO pricing and completion | Oct–Nov 2026 | Issue price, discount, take-up, specific-person allocations |
| Monthly revenue (MOPS, by the 10th of each month) | Monthly | Electronic Chemicals YoY; total YoY against tough comps from Mar 2026 |
| Q3 2026 results | Mid-Nov 2026 | Gross margin above 21%? Operating vs. non-operating profit mix |
| PSPI qualification news | Ongoing | Formal adoption by an advanced-packaging customer (company confirmation, not press) |
| New photoresist and electronic lines start-up | 2026–2027 | Utilisation; contract pricing mechanism changes |
| FY2026 results and dividend decision | Mar 2027 / AGM May 2027 | Resumption of dividends; FY2026 EPS |
| USD/TWD | Ongoing | Each 1% move ≈ 0.3–0.4% of gross profit |
| US tariff policy and textile demand | Ongoing | Color and Specialty order trends |
| Polytronics stake value | Ongoing | Effect on book value and comprehensive income |
Analyst verdict
Everlight Chemical is a credible but early-stage transformation story. A family-controlled Taiwanese dye maker with sub-cost-of-capital returns is being re-priced as a semiconductor-materials supplier. The operating evidence of a turnaround is real. Revenue is growing again (+11.6% for Jan–Aug 2026), Electronic Chemicals has overtaken Specialty Chemicals as the second-largest unit, quarterly EPS has gone from −NT$0.13 (Q2 2025) to +NT$0.19 (Q2 2026), and gross margin has recovered from a 15.95% trough. The contract-manufacturing route, building capacity for Japanese majors seeking Taiwanese localisation, is a lower-risk way into advanced-packaging chemistry than a pure own-brand push, and it uses Everlight's real strengths: synthesis depth, flexible plants and long-standing ITRI-derived photoresist know-how.
The equity, however, has moved well ahead of the fundamentals. At NT$48.60 the stock trades at roughly 3x book and around 370x trailing earnings, while the company's best return on equity in five years was 5.5%. The PSPI catalyst that fuelled the April 2026 surge remains, in management's own description, in sampling for advanced packaging, with Japanese incumbents preferred. About three-quarters of revenue still comes from FX-sensitive, competitively pressured legacy businesses. Free cash flow has nearly disappeared under a capex step-up, and management reversed its April statement on equity funding within four months by launching a roughly 9% dilutive SPO.
Overall, Everlight is a high-variance turnaround. It deserves close monitoring, but at current levels the risk-reward depends on outcomes that are not yet visible in reported numbers: a confirmed advanced-packaging PSPI win, sustained 21%+ gross margins, and a return to positive free cash flow after the new capacity is commissioned. Investors with a long horizon may prefer to wait for SPO pricing, Q3 2026 margins and formal qualification news before taking a position. Shorter-horizon participants should expect continued narrative-driven volatility.
APPENDIX — SOURCES
-
StockAnalysis.com (S&P Global Market Intelligence data): Overview, Financials, Balance Sheet, Cash Flow, Ratios — https://stockanalysis.com/quote/tpe/1711/
-
Simply Wall St, Past earnings (R&D, G&A) — https://simplywall.st/stocks/tw/materials/twse-1711/everlight-chemical-industrial-shares/past
-
Yahoo Finance 1711.TW — https://finance.yahoo.com/quote/1711.TW/
-
Yahoo Taiwan (MOPS syndication): revenue, EPS, dividends, announcements — https://tw.stock.yahoo.com/quote/1711.TW/revenue ; https://tw.stock.yahoo.com/quote/1711/announcement ; https://tw.stock.yahoo.com/quote/1711.TW/dividend ; https://tw.stock.yahoo.com/quote/1711.TW/eps
-
MOPS capital-increase filings via MoneyDJ / GeneOnline / Yahoo — https://www.moneydj.com/kmdj/news/newsviewer.aspx?a=a5b87692-8fbf-4ed1-a769-6faf384bf07f
-
Investing.com earnings history — https://www.investing.com/equities/everlight-chem-earnings
-
ROIC.ai overview — https://www.roic.ai/quote/1711.TW
-
Fugle (28 Apr 2026 investor conference notes) — https://blog.fugle.tw/post/earnings-call-1711-2026-04-28
-
BigGo Finance (FY2025 conference) — https://finance.biggo.com.tw/news/TW_1711.TW_2026-04-28
-
vocus.cc conference summaries (26 Aug 2025; 28 Apr 2026) — https://vocus.cc/article/68add410fd89780001a5c473 ; https://vocus.cc/article/69f2dad3fd897800017d451b
-
UDN / Economic Daily News: Apr 2026 conference, Jun and Aug 2026 revenue, 6 Oct 2026 limit-up and SPO — https://money.udn.com/money/story/5710/9470109 ; https://udn.com/news/story/7252/9612944 ; https://money.udn.com/money/story/5710/9743601 ; https://money.udn.com/money/story/5607/9797718 ; https://money.udn.com/money/story/5607/9447586 ; https://money.udn.com/money/story/5710/9380293 ; https://money.udn.com/money/story/5607/9429371
-
China Times / Wantrich: Nov 2025 results; Apr 2026 conference — https://wantrich.chinatimes.com/news/20251230900288-420101 ; https://wantrich.chinatimes.com/news/20260428900679-420101
-
Commercial Times: Polytronics stake (Apr 2026); toner subsidiary (2010) — https://www.ctee.com.tw/news/20260415700243-439901 ; https://www.ctee.com.tw/news/20100212700037-439901
-
cnyes: Aug 2026 revenue; price alerts — https://news.cnyes.com/news/id/6600677
-
HiStock: ownership, dividends — https://histock.tw/stock/1711
-
Winvest / CMoney / ifa.ai / StatementDog: quarterly margins and price data — https://winvest.tw/Stock/Symbol/Comment/1711 ; https://www.cmoney.tw/forum/stock/1711 ; https://info.ifa.ai/tw-stock/1711 ; https://statementdog.com/analysis/1711/profit-margin
-
Company website: About, History, Locations, ESG — https://www.ecic.com/about/ ; https://www.ecic.com/about/history/ ; https://www.ecic.com/about/location/ ; https://www.ecic.com/esg/esg_reports/
-
Everlight 2023 and 2021 Sustainability Reports — https://www.ecic.com/image/2024/07/2023-ESG-Ch2-zh-w.pdf ; https://www.ecic.com/image/2022/09/ecic-esg2021ch.pdf
-
Everlight FDA EIR announcement (2020) — https://api.ecic.com/en/news-report-en/everlight-passed-the-inspection-of-usfda-in-2019/
-
Company registry (technews / twincn / datagovtw) — https://info.technews.tw/company/15458455 ; https://twincn.com/item.aspx?no=15458455
-
MOPS board-election announcements (2021, 2024) via Yahoo / E.Sun — https://m.esunsec.com.tw/news/instant-detail.aspx?id=%7B9608383C-C267-48CC-90B1-C8F39614F5A1%7D
-
Global Views (succession), Taiwan Panorama (history, UVA share) — https://www.gvm.com.tw/article/40328 ; https://www.taiwan-panorama.com/Articles/Details?Guid=205411a8-52b3-45ab-923e-f9a73ce8bee8
-
MOEA Green Factory registry (Plant 2) — https://greenfactory.ftis.org.tw/Industry/IndustryView/143
-
MoneyDJ wiki (segment mix, plants) — https://www.moneydj.com/kmdj/wiki/wikiviewer.aspx?keyid=41201b79-dccc-47ad-a536-598ff524e8ca
-
Yokogawa case study — https://www.yokogawa.com/tw/library/resources/references/successstory-everlight-chemical/
-
PharmaCompass / Pharmaoffer (API registrations) — https://www.pharmacompass.com/apis-products/everlight-chemical ; https://pharmaoffer.com/api-excipient-supplier/company/everlight-chemical
-
Manager Today (circular economy) — https://www.managertoday.com.tw/articles/view/68975
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background |
|---|---|---|---|
Chen Chien-hsin (陳建信) | Chairman (representing Yung De Investment) | Chairman since 2009 | Eldest son of founder Chen Ting-chuan. Nine-year succession track: chairman's assistant, then vice chairman, then chairman (Global Views, 2017). |
Chen Wei-wang (陳偉望) | President and Director | President since 1 Jan 2001 (registry) | Second son of the founder. PhD in Industrial Engineering, University of Michigan (1996). Joined as head of R&D, then Vice President, reaching President in about six years. ZDHC Foundation board member from 2017, the only non-brand representative. Public face of the company's circular-economy and green-chemistry agenda. |
Weng Kuo-pin (翁國彬) | Head of Finance Division; Spokesperson (acts as CFO) | Spokesperson since at least 2021 | Presents financials at investor conferences |
Other registered managers (2024 registry) | 杜逸忠, 陳清泰, 陳克倫, 葉順興, 李復興, 梁仁陽, 孫哲仁 | — | — |
“—” = not publicly disclosed.
Board of Directors
| Director | Category | Affiliation (per MOPS election announcement) |
|---|---|---|
Chen Chien-hsin (陳建信) | Corporate director rep. (Yung De Investment) | Chairman, Everlight Chemical |
Chen Ting-chi (陳定吉) | Director | Co-founder; long-time director |
Chen Wei-wang (陳偉望) | Director | President |
Chen Chien-ming (陳建銘) | Director | Director and General Manager, 全通科技 (toner subsidiary) |
Chen Ju-ai (陳如愛) | Director (new 2024) | Assistant VP, Suzhou Everlight; founder's daughter |
Li Yung-lung (李永隆) | Director | Long-time director |
Kan Wen-yuan (干文元) | Director | Chairman, China Chemical (中華化學) |
Lin Chao-wen (林昭文) | Director (new 2024) | — |
Yang Wei-wen (楊偉文) | Independent director | Associate Professor of Law, Kainan University |
Chang Yuan-chen (張原禎) | Independent director | Senior VP, ITRI technology-transfer affiliate (創新工業技術移轉) |
Lin Hsiu-yu (林秀玉) | Independent director (new 2024) | — |
Major Shareholders
| Holder category | Stake | Date | Source |
|---|---|---|---|
Directors and supervisors combined | 16.50% | 2 Oct 2026 | HiStock (TDCC-based) |
Foreign investors | 5.79% | 2 Oct 2026 | HiStock |
Large holders (>1,000 lots) | 39.04% | 2 Oct 2026 | HiStock |
Yung De Investment Co. (family holding company) | Board seat held via 6.745 million shares registered to the representative (registry); historically 63–85 million shares registered under the founder as Yung De representative | Registry snapshots | Registry |
Chen Ting-chi (陳定吉) | 11.80 million shares (registry) | Registry | — |
Chen Wei-wang (陳偉望) | 6.30 million shares | Registry | — |
Chen Chien-ming (陳建銘) | 3.89 million shares | Registry | — |
Competitive Landscape
Competitors by Segment
| Segment | Named competitors | Everlight positioning |
|---|---|---|
Color Chemicals | Zhejiang Longsheng Group (owner of DyStar), Zhejiang Runtu, Archroma (which acquired Huntsman Textile Effects in 2023), Kiri Industries (India), Atul Ltd (India), Colourtex (India) | Differentiation through ZDHC/bluesign compliance and digital inks. Disadvantaged on cost against Chinese integrated producers. |
Specialty Chemicals (UVA/HALS) | BASF (Tinuvin®/Chimassorb®), Songwon Industrial (Korea), ADEKA (Japan), Rianlon (利安隆, China), Clariant | Niche specialisation (agri-film, optics, contact lenses). |
Electronic Chemicals — photoresist / PSPI | Tokyo Ohka Kogyo (TOK), JSR, Shin-Etsu Chemical, Fujifilm Electronic Materials, DuPont, Merck/EMD Electronics; PSPI: Toray, Asahi Kasei, HD MicroSystems/Resonac, Fujifilm | Second- or third-source local supplier. Contract manufacturer for Japanese majors. Benefits from localisation. Small scale. |
Electronic Chemicals — Taiwan peers (equity comparables) | Sanfu Chemical (三福化, 4755), Tex Year (德淵, 4720), China Chemical (中華化, 1727), Chang Chun Group (private) | Same investor theme ("TSMC supply-chain materials") |
Toner | — | Shrinking, price-competitive. US customers seeking non-China sources. |
Pharmaceutical (prostaglandin APIs) | Yonsung Fine Chemicals (Korea), Chirogate International (Taiwan), Cayman Chemical (US), Chinese generic API makers | Small niche; regulatory track record (FDA VAI 2019) |
Competitor Detail
| Metric | Everlight (FY2025) |
|---|---|
Revenue | NT$7.57 bn |
Revenue growth | −7.3% |
Gross margin | 19.0% |
Operating margin | −2.6% |
R&D intensity | ≈5.0% |
Competitive Advantages & Vulnerabilities
| Advantages | Vulnerabilities |
|---|---|
Local (Taiwan) supply for semiconductor localisation | Customers prefer Japanese PSPI incumbents for permanent materials (management's own words) |
Existing ITRI-derived photoresist IP and 30 years of production | Contract-manufacturing pricing pre-agreed; Everlight absorbs cost swings |
Diversified chemistries cushion single-market shocks | Legacy segments (color, specialty, toner) shrank 8–14% in FY2025 |
ZDHC/bluesign leadership with brands | Dye overcapacity in China compresses prices |
Low leverage (D/E 0.35x) | About 80% USD revenue against a TWD cost base |
Recent Developments
--



